SCM
AARD

Silverarc Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Silverarc Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Sell
33,684
-270,255
-89% -$2.8M 0.01% 72
2025
Q4 		$3.99M Sell
303,939
-2,973
-1% -$37.1K 0.55% 44
2025
Q3 		$4.08M Buy
306,912
+20,105
+7% +$227K 0.55% 48
2025
Q2 		$3.88M Buy
286,807
+167,311
+140% +$1.72M 0.72% 32
2025
Q1 		$897K Buy
+119,496
New +$1.34M 0.18% 64

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Silverarc Capital Management's AARD Position: Q1 2026 in Review

Silverarc Capital Management reduced its Aardvark Therapeutics (AARD) stake by 89% in Q1 2026, selling an estimated $2.8M and leaving 33,684 shares worth $127K. The position accounts for 0.01% of the portfolio, ranked #72.

Silverarc Capital Management first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.08M in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Silverarc Capital Management held 33,684 shares of Aardvark Therapeutics worth $127K as of Q1 2026.
  • Silverarc Capital Management sold 270,255 Aardvark Therapeutics shares in Q1 2026, an estimated $2.8M.
  • Aardvark Therapeutics made up 0.01% of Silverarc Capital Management's portfolio in Q1 2026, its #72 holding.
  • Silverarc Capital Management first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Silverarc Capital Management's Aardvark Therapeutics position peaked at $4.08M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.